News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
QVT Financial LP
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/18/2023 |
SC 13D/A
| QVT Financial LP reports a 5% stake in MP Materials Corp. |
| 05/09/2023 |
SC 13D/A
| QVT Financial LP reports a 7.6% stake in MP Materials Corp. |
| 09/08/2022 |
SC 13D/A
| QVT Financial LP reports a 8% stake in MP Materials Corp. |
| 06/09/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/20/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/31/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/23/2020 |
SC 13D/A
| QVT Financial LP reports a 13.7% stake in MP Materials Corp. |
| 07/12/2019 |
SC 13D/A
| QVT Financial LP reports a 0% stake in Axovant Gene Therapies Ltd. |
| 07/12/2019 |
SC 13D/A
| QVT Financial LP reports a 0% stake in Arbutus Biopharma Corporation |
| 07/12/2019 |
SC 13D/A
| QVT Financial LP reports a 0% stake in Urovant Sciences Ltd. |
| 07/12/2019 |
SC 13D/A
| QVT Financial LP reports a 0% stake in Myovant Sciences Ltd. |
| 03/19/2019 |
SC 13D/A
| QVT Financial LP reports a 58.2% stake in Axovant Sciences Ltd. |
| 12/20/2018 |
SC 13D/A
| QVT Financial LP reports a 65.2% stake in Axovant Sciences Ltd. |
| 06/07/2018 |
SC 13D/A
| QVT Financial LP reports a 73.1% stake in Axovant Sciences Ltd. |
| 01/16/2018 |
SC 13D/A
| QVT Financial LP reports a 29.1% stake in Arbutus Biopharma Corporation |
| 10/17/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/20/2013 |
SC 13D/A
| QVT Financial LP reports a 8.3% stake in Vivus, Inc. |
| 11/04/2011 |
SC 13D/A
| ANADYS PHARMACEUTICALS INC reports a 0% stake in Anadys Pharmaceuticals, Inc. |
| 10/31/2011 |
SC 13D/A
| ANADYS PHARMACEUTICALS INC reports a 7.1% stake in Anadys Pharmaceuticals, Inc. |
| 10/25/2011 |
SC 13D/A
| ANADYS PHARMACEUTICALS INC has filed a Schedule 13D for Anadys Pharmaceuticals, Inc. |
| 10/20/2011 |
SC 13D/A
| ANADYS PHARMACEUTICALS INC has filed a Schedule 13D for Anadys Pharmaceuticals, Inc. |
| 07/12/2011 |
SC 13D/A
| TOP SHIPS INC. reports a 4.6% stake in Top Ships, Inc. |
| 03/10/2011 |
SC 13D/A
| Molecular Insight Pharmaceuticals, Inc. reports a 7.6% stake in TO SCHEDULE 13D to Schedule 13D WASHINGTON, DC 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 01/12/2011 |
SC 13D/A
| Molecular Insight Pharmaceuticals, Inc. reports a 7.6% stake in Schedule 13D Washington, DC 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED § 240.13d-1 § 240. Molecular Insight Pharmaceuticals, Inc. |
| 12/18/2009 |
SC 13D/A
| TOP SHIPS INC. reports a 7.2% stake in Top Ships, Inc. |
| 07/09/2009 |
SC 13D/A
| QVT Financial LP reports a 9.1% stake in Top Ships, Inc. |
| 06/30/2009 |
SC 13D/A
| QVT Financial LP reports a 9.1% stake in Top Ships, Inc. |
| 03/10/2009 |
SC 13D/A
| Form SC 13D/A -- General statement of acquisition of beneficial ownership [amend] |
| 12/08/2008 |
SC 13D/A
| QVT Financial LP reports a 9.6% stake in Top Ships, Inc. |
| 08/09/2007 |
SC 13D/A
|
SEC Filing in the EDGAR database
|
| 08/07/2007 |
SC 13D/A
|
SEC Filing in the EDGAR database
|
| 07/05/2007 |
SC 13D/A
|
SEC Filing in the EDGAR database
|
| 06/27/2007 |
SC 13D/A
|
SEC Filing in the EDGAR database
|
|
|